Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares gapped up before the market opened on Monday . The stock had previously closed at $13.08, but opened at $13.92. Astellas Pharma shares last traded at $13.50, with a volume of 247,274 shares traded.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ALPMY. Sanford C. Bernstein lowered shares of Astellas Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 2nd. Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Two research analysts have rated the stock with a Hold rating, According to MarketBeat, Astellas Pharma has an average rating of “Hold”.

Astellas Pharma Stock Performance

The stock has a market cap of $24.54 billion, a price-to-earnings ratio of 28.85 and a beta of 0.19. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.03 and a quick ratio of 0.80. The firm has a fifty day moving average of $11.63 and a 200 day moving average of $10.86.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Thursday, October 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.10. The business had revenue of $3.45 billion during the quarter, compared to the consensus estimate of $3.14 billion. Astellas Pharma had a return on equity of 22.21% and a net margin of 6.39%. As a group, sell-side analysts forecast that Astellas Pharma Inc. will post 0.42 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.